Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a standard of care for patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). The introduction of tyrosine kinase inhibitors (TKIs) to first-line therapy has improved overall outcomes; however, a significant proportion of patients still relapse after alloHSCT. Posttransplant TKI maintenance was demonstrated to reduce the risk of relapse in a large retrospective study and, therefore, should be considered a valuable option. This consensus paper, written on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, presents an overview of clinical studies on the use of TKIs after alloHSCT and proposes practical recommendations regarding the choice of TKI, treatment timing, and dosage. It is hoped that these recommendations will become the state of art in this field and, more importantly, lead to a reduction of Ph-positive ALL relapse after alloHSCT. Cancer 2016;122:2941-2951. © 2016 American Cancer Society.
Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland. sgiebel@io.gliwice.pl.
Sebastian
S
Giebel
Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Anna
A
Czyz
Institute of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, United Kingdom.
Oliver
O
Ottmann
Department of Hematology, Centre Hospitalier Universitaire Sart-Tilman, University of Liege, Belgium, France.
Frederic
F
Baron
Clinical Hematology and Cellular Therapy Department, Hospital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
Eolia
E
Brissot
Hematology and Bone Marrow Transplantation (BMT) Unit, San Raffaele Scientific Institute, Milan, Italy.
Fabio
F
Ciceri
Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
Jan J
JJ
Cornelissen
Hematology Department, August Pi i Sunyer Institute for Biomedical Research, Hospital Clinic, Barcelona, Spain.
Jordi
J
Esteve
Clinical Hematology and Cellular Therapy Department, Hospital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
Norbert-Claude
NC
Gorin
Department of Hematology and Transplantation, Vanderbilt University, Nashville, Tennessee.
Bipin
B
Savani
Department of Hematology and Oncology, Klinikum Augsburg, Ludwig-Maximilians-Universitaet, Munich, Augsburg, Germany.
Christoph
C
Schmid
Clinical Hematology and Cellular Therapy Department, Hospital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
Mohamad
M
Mohty
Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel.|European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Office, Hospital Saint-Antoine, Paris, France.
Arnon
A
Nagler
D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000209:etiology; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012955:Societies, Medical
D047428:Protein Kinase Inhibitors
Philadelphia chromosome-positive acute lymphoblastic leukemia; allogeneic hematopoietic stem cell transplantation; dasatinib; imatinib; maintenance therapy; nilotinib; recommendations; tyrosine kinase inhibitors